| |
Fig. 1. EphA7 is required for pronephros development. (A) Injection of the EphA7-ATG-MO reduced exogenous EphA7 level from stage11 embryos as revealed by western blot. α-tubulin, loading control. (B) Embryos injected bilaterally with the EphA7-ATG-MO developed pericardial edema (arrowhead) at stage 43. (C) Fluorescent dextran excretion assay showing the tubule defects in EphA7-ATG-MO injected embryos. The dashed regions are shown in enlarged views highlighting the reduction in tubular coiling on the injected side. (D–F) A transverse section of a stage 36 embryo showing a single enlarged pronephric tubule on the EphA7-ATG-MO injected side (the arrow in E) in contrast to the 5 normal pronephric tubules cross-sections on the control side (arrowheads in F). (G) Quantification of the effect of the EphA7-ATG-MO on pronephric tubule lumen. (H) Whole-mount in situ hybridization using probes against Lhx1, Pax2 and PDZK1 in stage 36 embryos injected with EphA7-mis-MO, EphA7-ATG-MO, EphA7-ATG-MO plus EphA7 mRNA (175 pg EphA7 rescue) or EphA7 mRNA alone. Control indicates the un-injected side. (I) Statistics of embryos showing deformed nephrostomes. (J) Statistics of embryos showing reduced expression level of PDZK1. |
